{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF-59", "query": { "intervention": "MF-59" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF-59&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T02:12:28.510Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04077424", "title": "Senescent Immunity in Elders and Vaccine Responses (SILVER)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Flu Vaccine" ], "interventions": [ { "name": "Fluzone-High Dose Quadrivalent", "type": "BIOLOGICAL" }, { "name": "Fluad", "type": "BIOLOGICAL" }, { "name": "Flublock", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "125 Years", "sex": "ALL", "summary": "65 Years to 125 Years" }, "enrollment_count": 10, "start_date": "2019-10-21", "completion_date": "2020-02-01", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04077424" }, { "nct_id": "NCT03122223", "title": "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC-HIV (vCP2438)", "type": "BIOLOGICAL" }, { "name": "Bivalent subtype C gp120/MF59", "type": "BIOLOGICAL" }, { "name": "Bivalent subtype C gp120/AS01(B)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 160, "start_date": "2018-01-16", "completion_date": "2020-07-30", "has_results": true, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 9, "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03122223" }, { "nct_id": "NCT01855945", "title": "Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prophylaxis of A/H3N2v Influenza" ], "interventions": [ { "name": "Swine Influenza", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "92 Years", "sex": "ALL", "summary": "3 Years to 92 Years" }, "enrollment_count": 627, "start_date": "2013-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 11, "location_summary": "Redding, California • Sacramento, California • Lenexa, Kansas + 8 more", "locations": [ { "city": "Redding", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01855945" }, { "nct_id": "NCT00000946", "title": "A Study to Test the Safety of Three Experimental HIV Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "HIV p24/MF59 Vaccine", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": null, "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000946" }, { "nct_id": "NCT06015282", "title": "The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Investigational aQIVc", "type": "BIOLOGICAL" }, { "name": "licensed QIVr", "type": "BIOLOGICAL" }, { "name": "licensed aQIV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seqirus", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 7741, "start_date": "2023-11-03", "completion_date": "2025-01-30", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 51, "location_summary": "Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Redding", "state": "California" }, { "city": "Milford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06015282" }, { "nct_id": "NCT03014310", "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Avian Influenza" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "MF59", "type": "DRUG" }, { "name": "Monovalent Influenza A/H5N8 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 388, "start_date": "2017-01-09", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03014310" }, { "nct_id": "NCT00001031", "title": "A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 296, "start_date": null, "completion_date": "1997-12", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 7, "location_summary": "Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001031" }, { "nct_id": "NCT02915016", "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA-HIV-PT123 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/MF59 vaccine", "type": "BIOLOGICAL" }, { "name": "Bivalent Subtype C gp120/AS01B vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 334, "start_date": "2016-12-07", "completion_date": "2020-02-12", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915016" }, { "nct_id": "NCT02839330", "title": "A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Avian Influenza" ], "interventions": [ { "name": "aH5N1c", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seqirus", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3196, "start_date": "2016-07-11", "completion_date": "2017-10-04", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 26, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02839330" }, { "nct_id": "NCT05608005", "title": "Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza", "Healthy Volunteers" ], "interventions": [ { "name": "Panblok + MF59 Dose 1", "type": "BIOLOGICAL" }, { "name": "Panblok + MF59 Dose 2", "type": "BIOLOGICAL" }, { "name": "Unadjuvanted Panblok Dose 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 581, "start_date": "2022-11-03", "completion_date": "2024-02-13", "has_results": true, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-09-04T02:12:28.510Z", "location_count": 16, "location_summary": "Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Saint Augustine", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608005" } ] }